PMID- 21204913
OWN - NLM
STAT- MEDLINE
DCOM- 20110628
LR  - 20220419
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Print)
IS  - 0306-5251 (Linking)
VI  - 71
IP  - 5
DP  - 2011 May
TI  - Cannabis-related hospitalizations: unexpected serious events identified through 
      hospital databases.
PG  - 758-65
LID - 10.1111/j.1365-2125.2010.03897.x [doi]
AB  - AIMS: Cannabis is the most prevalent illicit drug used worldwide and can be 
      responsible for serious health defects in users. However, the risk related to 
      cannabis consumption is not well established. The present study aimed to assess 
      cannabis-related adverse events leading to hospitalization, and to estimate the 
      corresponding annual risk for consumers. METHODS: Participants were patients 
      admitted to the public hospitals in the Toulouse area (France) between January 
      2004 and December 2007 in relation to the use of cannabis. Reasons for admission 
      and other occurring events were identified through hospital discharge summaries. 
      We described all observed adverse events (AEs) and estimated their regional 
      incidence on the basis of cannabis consumption data. RESULTS: We included 200 
      patients, and identified a total of 619 adverse events (AEs), one of which was 
      lethal. Psychiatric disorders involved 57.7% of patients and accounted for 18.2% 
      of AEs. Most frequent outcomes were central and peripheral nervous system 
      disorders (15.8% of AEs), acute intoxication (12.1%), respiratory system 
      disorders (11.1%) and cardiovascular disorders (9.5%). We estimated that in 2007 
      the incidence of cannabis-related AEs in the Midi-Pyrenees region ranged from 1.2 
      per 1000 regular cannabis users (95% confidence interval (CI) 0.7, 1.6) to 3.2 
      (95% CI 2.5, 3.9). CONCLUSIONS: Cannabis use is associated with complications, 
      considered to be serious since they lead to hospitalization. Beyond the 
      well-known and widely investigated psychiatric events, serious cerebro and 
      cardiovascular complications have been identified. These findings contribute to 
      improve the knowledge of cannabis-related adverse events.
CI  - British Journal of Clinical Pharmacology (c) 2011 The British Pharmacological 
      Society. No claim to original US government works.
FAU - Jouanjus, Emilie
AU  - Jouanjus E
AD  - Universite de Toulouse, UPS, Equipe de Pharmacoepidemiologie INSERM U 1027, 
      Faculte de Medecine, 37 allees Jules Guesde, F-31000 Toulouse, France. 
      jouanjus@cict.fr
FAU - Leymarie, Florence
AU  - Leymarie F
FAU - Tubery, Marie
AU  - Tubery M
FAU - Lapeyre-Mestre, Maryse
AU  - Lapeyre-Mestre M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
SB  - IM
MH  - Adult
MH  - Cardiovascular Diseases/epidemiology/etiology
MH  - Female
MH  - France/epidemiology
MH  - Hospitalization/*statistics & numerical data
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Marijuana Abuse/complications/*epidemiology
MH  - Mental Disorders/epidemiology/etiology
MH  - Nervous System Diseases/epidemiology/etiology
MH  - Respiration Disorders/epidemiology/etiology
PMC - PMC3093081
EDAT- 2011/01/06 06:00
MHDA- 2011/06/29 06:00
PMCR- 2012/05/01
CRDT- 2011/01/06 06:00
PHST- 2011/01/06 06:00 [entrez]
PHST- 2011/01/06 06:00 [pubmed]
PHST- 2011/06/29 06:00 [medline]
PHST- 2012/05/01 00:00 [pmc-release]
AID - 10.1111/j.1365-2125.2010.03897.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 2011 May;71(5):758-65. doi: 
      10.1111/j.1365-2125.2010.03897.x.